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Amino acid analysis, sequence





PRELIMINARY PHYSICAL CHARACTERIZATION OF BIOPHARMACEUTICALS
Prior to beginning
Key
(X, Y)  = (amount of protein necessary (mg), concentration range over 
which measurements are possible (mg/ml)
A = alter temperature (typically 2- 90 C, 2-5 C intervals)
B = alter pH (typically 3, 4, 5, 6, 7, 8)
C = alter buffer (e.g., phosphate [1-3, 6-8, 11-13], citrate [2-4, 4-6, 5-
6.5], acetate [4-6], glycine [7-9], tris [7-9])
D = alter ionic strength (e.g., 0-3 M NaCl, typically 0, 0.01, 0.1, 1 M)
E = alter solute (urea, Gdn HCl, LiClO4, TFE, etc. 0-high molarity)
* = potentially applicable to solid states
BSA
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Empirical phase diagrams
Multiple analytical techniques employed to characterize the 
physical properties of protein therapeutics under various 
solution conditions (experimental parameters, i.e. pH and 
temperature)
A multidimensional phase space approach used to describe 
patterns connecting resultant complex data sets
Empirical phases identified to represent parameter regions 
with substantially uniform and coherent structural data
A phase diagram constructed employing an RGB color system 
to allow visualization and interpretation of the complex data 
sets







































































































































































































































































































































































































































































description for all the 
experimental data at each 
coordinate (each discrete 
parameter combination)
Construct density matrix 
including all the vectors 
and calculate the 
eigenvalues and 
eigenvectors 
Re-describe all the 
experimental data under a 
new basis set, which is 
constructed by eigenvectors
According to the magnitude of 
eigenvalues, truncate the re-
descriptions to smaller-







































A set of variables (experimental data) associated with each coordinate was 
used to construct the vector   
6
Visualization
Reconstructed 3-D Vector ( )321, xxxvi TpH =
Rescale the vector to RGB color system
( ) 10      '''' '321, ≤≤= ii TpH xxxxv
Each vector will define a color block in the phase 

































Bovine Granulocyte Colony Stimulating Factor
(bGCSF)
7
Kueltzo, L.A., Ersoy, B., Ralston, J.P., and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1805-1820.
Kueltzo, L.A., Ersoy, B., Ralston, J.P., and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1805-1820.
8
Kueltzo, L.A., Ersoy, B., Ralston, J.P., and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1805-1820.
Kueltzo, L.A., Ersoy, B., Ralston, J.P., and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1805-1820.
9
Kueltzo, L.A., Ersoy, B., Ralston, J.P., and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1805-1820.
Kueltzo, L.A., Ersoy, B., Ralston, J.P., and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1805-1820.
10
Kueltzo, L.A., Ersoy, B., Ralston, J.P., and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1805-1820.
Kueltzo, L.A., Ersoy, B., Ralston, J.P., and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1805-1820.
11
Kueltzo L.A. and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1793-1804.
Kueltzo L.A. and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1793-1804.
12
Kueltzo L.A. and Middaugh, C.R.  J. Pharm. Sci. (2003) 92 1793-1804.
Kueltzo L.A. and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1793-1804.
13
Kueltzo L.A. and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1793-1804.
Kueltzo L.A. and Middaugh, C.R.  J. Pharm. Sci. (2003) 92, 1793-1804.
14






Figure 1.  Second derivative UV spectrum 
showing the six negative peaks observed for 
recombinant ricin toxin A-chain.
















































































































































Figure 2.  Shifts in second derivative UV peak 
position as a function of pH and temperature.
17
Figure 3.  Phase diagram created using high-
resolution second derivative UV spectroscopy data. 







T Ricin- - 2nd Derivative UV
Figure 4.  Turbidity of recombinant ricin toxin A-chain 
as a function of temperature and pH determined by 



























Figure 5.  Effect of temperature and pH on the 
intrinsic Trp fluorescence intensity of recombinant 
ricin A-chain.






















Figure 6.  Effect of temperature and pH on the 
intrinsic Trp fluorescence peak position of 
recombinant ricin toxin A-chain.





















Figure 7.  Circular dichroism wavelength scan at 10oC 
of recombinant ricin toxin A-chain






















Figure 8.  Circular dichroism thermal melt of 



























Figure 9.  Effect of temperature and pH on the ANS 
fluorescence intensity of recombinant ricin toxin A-
chain.
























Figure 10.  Effect of temperature and pH on the ANS 
fluorescence peak position of recombinant ricin toxin 
A-chain.




















Figure 11.  Phase diagram generated using ANS fluorescence 
and intrinsic Trp fluorescence intensity data and CD molar 
ellipticity data of recombinant ricin toxin A-chain. 











































195 205 215 225 235 245 255





































































































Fig 6. Phase diagram rPA based on intrinsic, ANS 
binding fluorescence and CD
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Representative UV absorbance spectrum of 
RSV (solid line) and its second derivative 
(dotted line)
The spectrum was obtained at a viral protein concentration of 
0.3 mg/mL at 10 °C, pH 7. Ausar, et al, Mol. Pharm., 2 (6), 491 -499, 2005. 
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High-resolution second-derivative UV 
spectroscopy negative peak positions 
as a function of temperature for RSV 
at pH 7
Peaks below 270 nm (A, B, and C) cannot be definitively 
assigned due to the overlapping absorbance of Phe and 
the RNA core. Peaks near 277 nm (D), 284 nm (E), and 
292 nm (F) are attributed to the absorbance of Tyr, a 
combination of Tyr/Trp and Trp, respectively. 
Ausar, et al, Mol. Pharm., 2 (6), 491 -499, 2005. 
Optical density at 350 nm of RSV at 10 
°C as a function of pH
Viral protein concentration was approximately 0.3 mg/mL (n =3)
Ausar, et al, Mol. Pharm., 2 (6), 491 -499, 2005. 
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Ausar, et al, Mol. Pharm., 2 (6), 491 -499, 2005. 
Optical density at 350 nm (OD) 
versus temperature for RSV (0.3 
mg/mL protein) at pH 3-8 (n = 3) 
Relative extrinsic fluorescence 
intensity of ANS at 485 nm versus 
temperature for RSV at pH 3-8
Ausar, et al, Mol. Pharm., 2 (6), 491 -499, 2005. 
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Ausar, et al, Mol. Pharm., 2 (6), 491 -499, 2005. 
Relative CD signal at 222 nm 
as a function of temperature 
for RSV at pH 3-8 
Quaternary structural analysis of RSV by 
dynamic light scattering over the pH range 6-8 
Panels are arranged from top to bottom as effective diameter, 
scattering count rate, and polydispersity index, respectively.
Ausar, et al, Mol. Pharm., 2 (6), 491 -499, 2005. 
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Empirical phase diagram (EPD) of RSV 
over the pH range 3-8
Data included in the generation of the EPD are all negative second-derivative UV peaks, CD signal at 
222 nm, optical density at 350 nm, intrinsic fluorescence peak position, intrinsic fluorescence intensity 
at 330 nm, and ANS fluorescence intensity at 485 nm















Figure 1. (A) Surface representation of 3-dimensional structure NVLP viewed along icosahedral 3-fold 
axes. (B) Central section along icosahedral 3-fold axis. S domains associate to form contiguous shell 
from which arches containing subdomains P1 and P2 emanate. (C) x-ray crystallographic structure of 
recombinant NV capsid protein. (Adapted from Prasad, et al, J Infec Dis 200,181:S317-321)
CD spectra of NV-VLPs at various 
pH values



























The spectra presented are an average of three consecutive scans
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CD temperature studies of NV-VLPs. Mean residue molar ellipticity at 222 nm as a function of 
temperature over a range of pH 3-8 (A). The CD spectra at pH 7.0 were collected as a function 
of temperature (B) and the distribution of secondary structure was estimated by the program 
CDSSTR (C).




























































































































































































Second derivative UV absorbance 
studies of NV-VLP
UV zero order (solid line) and second derivative (dotted line) absorbance 
spectra of NV-VLP at pH 7 (A). The position of the wavelength minima of 
phenylalaninne (B), tyrosine (C) and tryptophan (D) minima are plotted as a 
function of pH at 10° C. (n=3). 
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Second derivative absorbance minima arising from phenylalanine (A and B), a 
combination of phenylalanine and tyrosine (C), tyrosine (D), and a combination of 
tyrosine and tryptophan (E) and tryptophan  (F) were monitored as a function of 
temperature at pH 7. (n=3).
















































Tryptophan emission fluorescence of NV-VLPs as a function 
of pH and temperature






































































































NVLPs suspensions at pH 3 to 8 were heated from 10 to 90 ° and the fluorescence emission maxima (solid circles) or the 
intensity at 330 nm (empty circles) were monitored. Error bars represent the standard error (n=3).
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ANS Fluorescence intensity of 
NVLP as a function of pH and 
temperature 
NVLPs suspensions in the presence of 40 mM 8-anilino-
1-naphthalene sulfonate (ANS) were excited at 385 nm 
and the fluorescence intensity at 485 nm was monitored 
as a function of temperature at each indicated pH. Error 
bars represent the standard error (n=3).






































































pH 3 pH5 
A 
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pH 6 pH 7 pH 8 
Analysis of the quaternary structure 
of NV-VLP as a function of pH by 
DLS and TEM 
(A) NV-VLPs were dialyzed overnight against 
citrate/phosphate buffer at the indicated pH and 
the particle size was determined by DLS (open 
circles) or by TEM (black squares). (B) Morphology 
of NV-VLPs at different pH values at 10 °C using 1 
% Ammonium molybdate as a negative stain. 
(Bar= 50nm).
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Analysis of the quaternary 
structure of NV -VLPs as a 
function of pH and temperature
 
































65 °C 25 °C 85 °C 
(A) The size of NV-VLPs suspended at different pH values was monitored as a function of temperature 
by DLS. (B) The morphology of NV-VLPs (pH 7) at different temperatures was studied by TEM using 1% 
Ammonium molybdate as a negative stain. (Bar= 50nm)
Empirical phase diagram for NV-VLPs based on UV, intrinsic and 
extrinsic fluorescence, and CD results
pH























Four distinct phases (P) are observed: P1: NV-VLP in native, intact form; P2: disassembled capsids; P3: unfolded 
soluble capsids; P4: aggregated capsids. Blocks of continuous color represent single empirically defined phases, 
conditions under which raw data-derived vectors behave similarly. The colors themselves have no direct physical 
meaning.
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DSC analysis of full length NV-VLP (panel A) and the isolated P-

































































pH dependence of the transition temperatures (Tms) obtained by 
DSC analysis of the NV-VLP and P-domain























The endothermic transitions temperatures (Tm) obtained for full length NV-VLP (Tm1: black 
circles and Tm2: back squares) and isolated P-domain (empty circles) were plotted as a 
function of pH.
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Correction Matrices for ASPs and Neurotoxin ANS 
Fluorescence Data (ASP+[correction]=HT)
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Non-Viral Gene Delivery Vehicle DOTAP
Non-Viral Gene Delivery Vehicle DOTAP 
(Charge ratio =4.0)
40
Non-Viral Gene Delivery Vehicle 
DOTAP/DOPE
Non-Viral Gene Delivery Vehicle 
DOTAP/DOPE (Charge ratio = 4.0)
41
Non-Viral Gene Delivery Vehicle PLL
Non-Viral Gene Delivery Vehicle PLL (Charge 
ratio =4.0)
42
Non-Viral Gene Delivery Vehicle PEI
Non-Viral Gene Delivery Vehicle PEI (Charge 
ratio =4.0)
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oxalate         malonate       succinate      glutarate       adipate        pimelate       suberate azelaate
MacLean, D.S., Qian, Q., and Middaugh, C.R.  J. Pharm. Sci., (2002) 91, 2220-2229.
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Table 1. Inhibition of rPA thermal aggregation at 37°C by 
various GRAS excipients
Excipient 
Molar ratio  
(Excipient: PA), 
 Molarity (excipient) 




      
Sorbitol 20.00% 106 
Mannitol 10.00% 100 
Sodium Citrate 0.2 M 95 
Sodium Citrate 0.1 M 94 
Trehalose 20.00% 94 
Dextrose  10.00% 93 
Histidine 0.3 M 88 
Dextrose  20.00% 85 
Malic Acid 0.15 M 83 
Dietanolamine 0.3 M 62 
Sucrose 20.0% 59 
Glycerol 10.00% 48 
Sucrose 10.00% 46 
Tween 80 0.10% 46 
Brij 35 0.01% 41 
CaCl2 0.015 M 40 
Tween 20 0.10% 14 
2-OH propyl β-CD 5.00% 14 
Dextran T40 0.1 12 
α Cyclodextrin 2.50% 6 
Albumin 1.00% 0 
Pluronic F-68 0.05% -14 


























Fig 8. Increase of rPA thermal transition temperature by 
































Inhibition of Aggregation of recombinant ricin toxin A-
chain V76M/Y80A at 45oC by various GRAS excipients
% Inhibition
Pluronic F-68 (0.1%) 93%




Pluronic F-68 (0.05%) 78%
Glycerol (20%) 78%




Brij 35 (0.05%) *  73%






Heparan Sulfate (10x) 67%
Dietanolamine (0.3M) 67%
2-OH propyl γ -CD (5%) 66%
Gelatin (2.5%) 65%







Pluronic F-68 (0.01%) 62%
Mannitol (10%) 62%
2-OH propyl γ -CD (10%) 62%
2-OH propyl β-CD (5%) 60%
Heparin (10x) 58%
Phytic Acid (10x) 55%
Malic Acid (0.15M) 51%
Lactose (10%) 51%
Lactic Acid (0.15M) 49%
α Cyclodextrin (2.5%) 44%
Glu + Arg (0.05M each) 43%
Dextran Sulfate (10x) 42%
Lactose (1.7%) 36%
Heparin (1x) 13%
Sucrose Octasulfate (0.1x) 12%
Tween 80 (0.1%) 12%
Dextran Sulfate (0.1x) 10%
Tween 80 (0.05%) 10%
Dextran Sulfate (1x) 9%
Tween 80 (0.01%) 5%
Heparan Sulfate (1x) 3%
Phytic Acid (1X) 2%
Phytic Acid (0.1X) 2%
Heparin (0.1x) 2%
Heparan Sulfate (0.1x) 2%
Ascorbic acid (0.15M) AGG
Tween 20 (0.1%) -13%
Tween 20 (0.05%) -56%
Tween 20 (0.01%) -86%
SOS (1x) -10
*An initial increase in OD360 was observed.
49




































































Inhibition of RSV aggregation kinetics at 56°C 
by various excipients
Effect of various excipients on the aggregation kinetics 
of RSV. The excipient concentrations are indicated in 
each plot. For clarity reasons only the error bars for the 
control experiment are shown. All of the experiments 
were performed in triplicate.
Increase of the thermal transition of RSV by 
various GRAS excipients










































































































CD thermal melts of RSV samples in the presence of  stabilizers was monitored at 222 nm. A 
thermal melt of RSV samples without excipients (control) is also shown
50
A Generic Approach to the Identification of 
Stabilizers of Macromolecules
Characterization 
(CD, Fluorescence, SEC, LC, MS, etc.)
Phase Diagram (pH, T, ionic strength, redox)
(2nd derivative UV absorbance)
Accelerated stability Assay(s)
(LS, Fluor., DSC, etc.)
High throughput screening
















Pfizer – Todd Derrington
BD Technologies – Kevin Mar






(A) HP-SEC analysis of rhFVIII samples 
showing formation of aggregates with time. The 
data for the incubation time points have been 
stacked for easy visualization. From top to 
bottom: 0 h, 6 h, 1 day, 2 day, 3 day, 4 day, 5 
day, 6 day, and 7 day incubation time points. 
Gel filtration performed in 50 mM Tris, 400 mM 
NaCl, 5mM CaCl2, 0.05% NaN3, pH 7.0. The 
flow rate was 0.65mL/min
(B) Dynamic light scattering analysis of 
rhFVIII samples as a function of incubation 
time. The mean diameters obtained by second-
order cumulant (triangles) and NNLS (circles) 
analysis are shown. Protein concentration was 
~0.1mg/mL.
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
52
Biological Activity and Extent of Aggregation of RhFVIII
Samples as a Function of Incubation Time at 37 °C
2685 7 days 
18 92 6 days 
20 89 5 days 
20 92 4 days 
20 90 3 days 
15 97 2 days 
10 96 1 day 
0 101 6 h 
0 100 0 h 
% aggregation % activitytime
a Activity was determined from a one-stage activated partial thromboplastin time 
assay
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
(A) Far-UV CD spectrum of rhFVIII at 25 °C. (B) Fluorescence emission 
spectra of fractionated native (13.25  µg/mL, circles) and aggregate 
(19.17  µg/mL, triangles) species in 25 mM Tris, 300 mM NaCl, 4 mM 
CaCl2, pH 7 
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
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(A) Effect of temperature on rhFVIII fluorescence emission intensity at 
330 nm.
(B) Effect of temperature on the fluorescence emission maximum of 
rhFVIII (B). 
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
Effect of temperature on the fluorescence of bis-ANS in 
the presence of rhFVIII
A protein concentration of 0.1 mg/mL and bis-ANS concentration of 4 µM was used in 10 
mM MOPS, 150 mM NaCl, 4mM CaCl2, pH 7. Samples were incubated at each temperature 
for 3 min prior to spectra acquisition. Bis-ANS emission intensity measured at 500 nm.
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
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Effect of temperature on the molar ellipticity of 
rhFVIII at 215 nm 
A moving average of the raw data is shown by the dark line for easier 
visualization of the temperature profile.
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
(A)Effect of temperature on the amide I' IR spectrum of rhFVIII. (B) Deconvolution of 
the amide I' spectrum of rhFVIII obtained at 27 °C. (C) Deconvolution of the amide I' 
spectrum of rhFVIII at 90 °C. (D) Effect of temperature on the absorbance of rhFVIII
at 1618 cm-1.
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
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Effect of solute concentration on the wavelength of the fluorescence 
emission maximum of rhFVIII. GdnHCl is shown in squares, LiClO4 is 
shown in triangles, urea is shown in diamonds, and propanol is 
shown in circles 
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
(A) Effect of guanidine hydrochloride concentration on the temperature dependence of the 
fluorescence emission maximum of rhFVIII: rhFVIII (squares), rhFVIII + 0.5 M GdnHCl (triangles), 
and rhFVIII + 2 M GdnHCl (circles). (B) Effect of propanol concentration and incubation time (at 37  
°C) on rhFVIII size as determined by dynamic light scattering: time 0 (closed squares), day 1 (open 
circles), day 2 (closed triangles), day 3 (open squares), day 4 (closed diamonds), and day 5 (open 
triangles). (C) Effect of GdnHCl concentration and incubation time (at 37 °C) on rhFVIII size as 
determined by DLS: day 0 (closed squares), day 1 (open circles), day 2 (closed triangles), day 3 
(open squares), day 4 (closed diamonds). 
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
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Effect of temperature on the fluorescence wavelength 
emission maximum of rhFVIII in the absence (squares) 
and presence (circles) of 40 mM EGTA 
Grillo et al. Biochemistry, 40 (2), 586 -595, 2001
The Analysis and Stability of 
Proteins at High Concentration
57





membranes (blue) are 
represented. 
Figure from : Medalia, O.,  Weber, I.,  Frangakis, A. S., Nicastro, D.,  Günther Gerisch, G. 
and Baumeister, W. Science (2002) 298, 1209-1213.
Background
Crowded nature of cellular systems
Protein concentrations approaching 40% w/v






1   Lobo, 2004 J. Pharm. Sci.
2 Minton, 2005 J. Pharm. Sci.
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Excluded Volume Theory
- Ross and Minton, 1977, Analytical Biochemistry
- Minton, 2005 J. Pharm Sci.
Excluded Volume Theory cont’d.
- Minton, 2005 J. Pharm Sci.
A – Conformational stabilization
b – Colloidal destabilization
59
Potential Biophysical Methods to 




Ultra-high resolution near 
ultra-violet absorbance 
spectroscopy
















Develop methods to directly study high concentration protein solutions
Determine the effect of concentration on structure and stability
Model Proteins - Methods
bovine serum albumin 399 mg/mL DSC FTIR 
fibrinogen 50 mg/mL UV CD
lysozyme 350 mg/mL FSF DLS
hemoglobin 245 mg/mL Raman US
two monoclonal antibodies  up to 200mg/mL
bovine somatotropin in an oil suspension up to 400mg/mL




































































































































































Secondary structure analysis 
Sampling requirements
1-10 µL sample size
<10 µm path length
Spectral artifacts?
CD Spectral Artifact
A.  Representative IgG
spectra 
■ 0.1mg/mL 
□ 100mg/mL with 
excessively long path 
length
B.  A blown up 
representation of the 
100mg/mL spectrum 
C.  Representative 
spectra with effective 
path length reduction
2 0 0 2 1 0 2 2 0 2 3 0 2 4 0 2 5 0 2 6 0
- 4 .0 x 1 0 6
- 2 .0 x 1 0 6
0 .0
2 .0 x 1 0 6
4 .0 x 1 0 6
6 .0 x 1 0 6
8 .0 x 1 0 6
C
W a v e le n g th  (n m )
-3 x 1 0 5
-2 x 1 0 5
-1 x 1 0 5
0
1 x 1 0 5
















) - 4 .0 x 1 0
6
- 2 .0 x 1 0 6
0 .0
2 .0 x 1 0 6
4 .0 x 1 0 6
6 .0 x 1 0 6
8 .0 x 1 0 6
A
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Far UV CD – Model Proteins
A-D.  Ellipticity at 222nm
E-H.  Far UV CD spectra of 
proteins at 10°C and at 






C/G.  BSA 
0.6mg/ml; 399mg/ml 
D/H.  Fibrinogen 
0.2mg/ml; 59mg/ml 
 




























































Far UV CD – Monoclonal Antibodies
















































































































































Attenuated total reflectance FTIR
Infrared light is reflected through a crystal
At some points, this light penetrates into sample 
and is absorbed, creating a small effective path 
length.
65


































































































































































































































































































(―) 190mg/mL  
B.  Transmission spectra of 
the same solutions of MAb 1




(―) 180mg/mL  
D.  Transmission spectra of 
the same solutions of MAb 2 
 










































































Front Surface Fluorescence –
Model Proteins
A.i. λmax Lysozyme  
0.41mg/ml;         
350mg/ml 
A.ii. Intensity at 335nm
B.i. λmax Fibrinogen
0.17mg/ml;         
59mg/ml 
B.ii. Intensity at 336nm
C.i. λmax BSA
0.55mg/ml;         
399mg/ml 
C.ii. Intensity at 339nm
 








































































































































































Front Surface Fluorescence Summary











High Resolution 2nd Derivative UV 
Absorbance
Absorbance requirements
1-10 µm path length 
<1.5 AU
OD350nm
2nd derivative peak positions of aromatics
70
2nd Derivative UV Absorbance -
Hemoglobin
 








































































































































































































































2nd Derivative UV Absorbance –
MAb 1































































































2nd Derivative UV Absorbance –
MAb 2










































































































0.55mg/ml      
399mg/ml
 



































































































Optical Density - MAbs


























Signal Generator Signal Analyzer
Sample Cell 













Frequency (Hz) Frequency (Hz) 
Bandwidth Bandwidth 
Piezoelectric Transducer (1) 
aggregation and 
unfolding
US – 100mg/mL IgG
























• Although no relative 
stability obtained yet, 
potential for compressibility 
information (dynamic) with 
this technique.
• Orthogonal method to 




Protein DSC UV(°C) O.D.350nm Fluorescence(°C) CD 
(°C) (°C) peak4 peak5 peak6 (°C) λmax Intensity (°C) 
Lysozyme 
 





350mg/ml 73.2 72.5 73.3±1.2 73.3±1.2 69.3±0.4 75 72.5 74 
Hb 
 
0.3mg/ml 67.0±0.4 62.5 61.3±1.3 63.8±1.3 58.7±0.6 * * 73±1.5 
245mg/ml 75±0.7 64±1 71±2 72±1 68.3±1.2 * * 73±0.5 
Fibrinogen 
 
0.17mg/ml 50.7±0.2 50±2.0 50 50 53.1±1.1
42.5
±2.5 47.5 47.5 





78±0.2 60a 51.3±1.3a 50a 63.2±0.2 40a 46.3±1.3a 73.5±1 
399mg/ml 76 75a 67.5a 60a 80 60a 62.5a 78.9±0.5 
 






















MAb 2 Empirical Phase Diagram Temp. vs. Concentration (pH 6)
T
Concentration
bST in Sesame Oil
78
bST in Sesame Oil
ATR-FTIR - bST


















































□ Representative oil lot 
(380mg/mL)
■ 10mg/mL bST in pH 9.5 sodium 
bicarbonate solution
Increased stability of oil lot 
over aqueous solution
Similar helical/random 
content in oil and aqueous 
environments
Altered sheet and turn 
contents in oil 
79
Front Surface Fluorescence - bST









































■ Representative oil lot 
(380mg/mL)
● 10mg/mL bST in pH 9.5 
sodium bicarbonate solution
▲ 1mg/mL bST in pH 9.5 sodium 
bicarbonate solution
• Differences in peak position 
may reflect the different nature 
of the samples and not a real 
structural change 
•Oil formulations are more 
stable than aqueous solutions
• 10mg/mL bST solution is less 
stable than 1mg/mL bST
solution
Front Surface Fluorescence – bST













































1 – Representative oil spectra of high milk producing
lot






















Aim: Measure the fluorescence 
properties of samples containing 
increasing aggregate content to 
elucidate the cause of the 
altered spectral signatures
Front Surface Fluorescence - bST













































































• 3 – 13.5% aggregate
• 4 – 20.6% aggregate
• 5 – 1.8% aggregate
• Severe spectral distortion of high aggregated 
samples
• Previous spectral changes not due to increased 
scattering
• Spectral changes likely due to structural 
perturbation
• Assay demonstrates correlation between 
fluorescence spectral signals (peak and intensity) 
with increasing aggregate





Secondary Structure – largely stabilized (ex. 
lysozyme)
Tertiary Structure – Variable (decrease – Mabs; 
increase – Hb) 
Colloidal Stability
Variable  (decrease – lysozyme and MAbs; 
increase – Hb)
The Future
Identifying other driving forces that dictate the stability of 
proteins at high concentration (other than thermodynamics)
Kinetics - Ea
Dynamics – flexibility, mobility
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